Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Annals of Oncology Year : 2010

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Abstract

Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.

Domains

Immunology

Dates and versions

inserm-00484825 , version 1 (19-05-2010)

Identifiers

Cite

Arlene Chan, D. W. Miles, Xavier B. Pivot. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.. Annals of Oncology, 2010, 21 (12), pp.2305-15. ⟨10.1093/annonc/mdq122⟩. ⟨inserm-00484825⟩

Collections

INSERM UNIV-FCOMTE
48 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More